Mabwell announced that its wholly-owned subsidiary T-mab has successfully passed ANVISA’s GMP on-site inspection in Brazil. The approval supports continued biopharmaceutical manufacturing compliance, which is generally a positive regulatory milestone but is not detailed with any financial impact in the release.
Mabwell announced that its wholly-owned subsidiary T-mab has successfully passed ANVISA’s GMP on-site inspection in Brazil. The approval supports continued biopharmaceutical manufacturing compliance, which is generally a positive regulatory milestone but is not detailed with any financial impact in the release.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
